Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00773513
Other study ID # BH21260
Secondary ID 2007-005129-31
Status Completed
Phase Phase 4
First received
Last updated
Start date December 12, 2008
Est. completion date July 27, 2017

Study information

Verified date August 2019
Source Hoffmann-La Roche
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This 2 arm safety study will compare the outcome with respect to a composite endpoint of all-cause mortality and non-fatal cardiovascular events (myocardial infarction, stroke) in CKD participants either on dialysis or not receiving renal replacement therapy under treatment with methoxy polyethylene glycol-epoetin beta or reference ESAs. Participants will be randomized to receive intravenous (iv) or subcutaneous (sc) methoxy polyethylene glycol-epoetin beta at the following doses: for participants not already receiving ESA treatment, methoxy polyethylene glycol-epoetin beta will be administered at a starting dose of 0.6 micrograms per kilograms every 2 weeks (mcg/kg/2wks) iv or sc; for participants receiving maintenance ESA treatment, iv or sc methoxy polyethylene glycol-epoetin beta will be administered at an initial monthly dose of 120, 200 or 360 micrograms (mcg) depending on the weekly dose of ESA received prior to first methoxy polyethylene glycol-epoetin beta administration. Participants randomized to reference ESA treatment will receive iv or sc ESAs in accordance with their prescribed dosing information.


Recruitment information / eligibility

Status Completed
Enrollment 2825
Est. completion date July 27, 2017
Est. primary completion date July 27, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female participants with symptomatic anemia associated with CKD

- Participants with renal anemia who are not treated with an ESA:

- Anemia was defined as hemoglobin (Hb) concentration less than (<) 11.0 grams per deciliter (g/dL) (mean of 2 screening values with at least one day and a maximum of 2 weeks between measurements) with clinical indication for ESA treatment

- Participants with renal anemia who are on maintenance ESA therapy:

- If on dialysis: regular long-term hemodialysis or peritoneal dialysis therapy with the same mode of dialysis for at least 3 months before screening

- Hb concentration between 10 and 12 g/dL (mean of 2 screening values with at least one day and a maximum of 2 weeks between measurements)

- Participants with adequate iron status defined as: serum ferritin above or equal to 100 micrograms per liter or transferrin saturation above or equal to 20 percent

Exclusion Criteria:

- Contraindications to ESA treatment: uncontrolled hypertension, hypersensitivity to the active substance or any of the excipients, any other contraindication to ESA therapy

- Conditions known to cause inadequate response to ESA treatment or anemia other than symptomatic anemia associated with CKD:

- History of hemoglobinopathy

- Anemia due to hemolysis

- Pure red cell aplasia

- High likelihood of early withdrawal (for example, within 1 year) or interruption of the study

- Pregnancy or breast-feeding

- Women of childbearing potential without effective contraception

- Administration of another investigational drug within 1 month before screening or planned during the study period

Study Design


Intervention

Drug:
Darbepoetin Alfa
Darbepoetin alfa will be administered as per approved label.
Epoetin Alfa
Epoetin alfa will be administered as per approved label.
Epoetin Beta
Epoetin beta will be administered as per approved label.
methoxy polyethylene glycol-epoetin beta
Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)

Locations

Country Name City State
Argentina Fresenius Medical Care Martinez Buenos Aires
Argentina Fresenius Medical Care Morón Buenos Aires
Argentina Fresenius Medical Care San Martin Buenos Aires
Argentina Fresenuis Medical Care Mansilla Caba
Australia ROYAL ADELAIDE HOSPITAL; Renal Clinical Trials, CNARTS Adelaide South Australia
Australia Cairns Hospital; Renal Services Cairns Queensland
Australia Monash Medical Centre; Renal Transplant Unit Clayton Victoria
Australia Gosford Hospital; Renal Gosford New South Wales
Australia Renal Research Dr Simon Roger Gosford New South Wales
Australia Launceston General Hospital; Diabetes and Renal Research Unit Launceston Tasmania
Australia Royal Perth Hospital; Nephrology Perth Western Australia
Australia Gold Coast Hospital Department of Pharmacology & Therapeutics Southport Queensland
Belgium UZ Brussel Brussel
Belgium UZ Gent Gent
Belgium Jessa Zkh (Campus Virga Jesse) Hasselt
Belgium UZ Leuven Gasthuisberg Leuven
Belgium AZ Delta (Campus Wilgenstraat) Roeselare
Brazil PUCPR Curitiba PR
Brazil Centro Mineiro de Pesquisa - CMIP Juiz de Fora MG
Brazil Hospital Sao Lucas - PUCRS Porto Alegre RS
Brazil Santa Casa de Misericordia de Porto Alegre Porto Alegre RS
Brazil Hospital Univ. Pedro Ernesto - Hupe; Nefrologia Rio de Janeiro RJ
Brazil Beneficencia Portuguesa de Sao Paulo Sao Paulo SP
Brazil Clinica de Medicina Interna e Nefrologia (CMIN) Sao Paulo SP
Brazil Hospital das Clinicas - FMUSP; Nefrologia Sao Paulo SP
Brazil Universidade Federal de Sao Paulo - UNIFESP Sao Paulo SP
Brazil Instituto de Hemodialise Sorocaba Sorocaba SP
Croatia General Hospital Karlovac; Dept of Haemodialysis Karlovac
Croatia Clinical Hospital Osijek; Dept of Haemodialysis Osijek
Croatia Clinical Hospital Center Rijeka; Dialysis Rijeka
Croatia General Hospital Josip Bencevic; Department of Haemodialysis Slavonski Brod
Croatia Clinical Hospital Split; Dialysis Split
Croatia General Hospital Zadar; Dialysis Zadar
Croatia Klinicki Bolnicki Centar Zagreb; Dialysis Zagreb
Czechia Fakultni Nemocnice Kralovske Vinohrady (FNKV); Interni Hematologicka Klinika Hradec Kralove
Czechia Faculty Hospital; Dialysis Unit Ostrava
Czechia Institut Klinicke A Experimentalni Mediciny Klinika Nefrologie Praha
Czechia Nemocnice Strahov; Interni Oddeleni-Strahov Praha 6
France Centre Hospitalier; Hemodialyse Annonay
France Hopital Pellegrin; Departement Nephrologie Bordeaux
France Centre Hospitalier Du Dr Duchenes; Service De Nephrologie & Hemodialyse Boulogne
France Hopital La Cavale Blanche; Nephrologie Brest
France Hopital Louis Pasteur; Nephrologie - Hemodialyse Colmar
France Clinique Lambert; Service de Néphrologie dialyse La Garenne-Colombes
France Chu Dupuytren; Nephrologie-Hemodialyse Limoges
France Aural Lyon
France Hopital Edouard-Herriot; Nephrologie - Hemodialyse Lyon
France Centre Hospitalier Les Chanaux; Service de Néphrologie Unité 12 Macon
France Service de Nephrologie & D'Immunologie; Clinique Nantes
France Centre Hospitalier Uni Ire Gaston Doumergue; Service D'Hemodialyse Nimes
France Aura - Centre Henri Kunt Ziger Paris
France Hopital Laennec; Echo Saint Herblain
France Hopital Sud ; Nephrologie Hemodialyse Salouel
France Hopital Civil; Nephrologie Clinique Medicale B Strasbourg
France Hopital Rangueil; Nephrologie Hemodialyse Toulouse
France Ch De Valenciennes; Nephrologie Valenciennes
Germany Gemeinschaftspraxis Dr. Stefan Zinn und Steffen Hengst Alsfeld
Germany KFH Nierenzentrum Bad Hersfeld; Nephrologie Bad Hersfeld
Germany Universitätsklinikum Bonn; Medizinische Klinik und Poliklinik I; Allgemeine Innere Medizin Bonn
Germany Dialysepraxis Dr. med. Uwe Kraatz Demmin
Germany DaVita Clinical Research Deutschland GmbH Düsseldorf
Germany Universitätsklinikum Duesseldorf; Klinik fuer Nephrologie Düsseldorf
Germany Universitätsklinikum Erlangen; Medizinische Klinik 4; Nephrologie und Hypertensiologie Erlangen
Germany Georg-Haas-Dialysezentrum der PHV Gießen
Germany Nephrologische Schwerpunktpraxis; Hamburg Barmbek Hamburg
Germany Klinikum Hann. Münden, Nephrologisches Zentrum Niedersachsen Hann. Münden
Germany Uniklinikum Heidelberg Heidelberg
Germany Universitaetsklinikum des Saarlandes; Klinik f. Innere Medizin IV Homburg/Saar
Germany UNI-Klinikum Campus Kiel Klinik f.Innere Medizin IV Kiel
Germany KfH Kuratorium für Dialyse und Nierentransplantation e.V.; KfH-Nierenzentrum München
Germany KFH Nierenzentrum Oberschleissheim Oberschleissheim
Germany Dres. Roland Erwin Winkler Ann Michelsen Dietmar Sehland u.w. Rostock
Germany Praxis Dr.med. Joachim Leicht Schwandorf
Germany Robert-Bosch-Krankenhaus; Allgemeine Innere Medizin und Nephrologie Stuttgart
Greece Uni Hospital of Alexandroupoli; Nephrology Dept. Alexandroupolis
Greece Laiko General Hospital; Nephrology Div. Athens
Greece Uni Hospital of Ioannina; Nephrology Dept. Ioannina
Greece Univeristy Hospital of Larissa; Nephrology Larissa
Greece Hippokratio Hospital; Nefrology Thessaloniki
Israel Rabin MC- Belinson campus Petach Tikva
Israel Rabin MC- Hasharon campus Petah Tikva
Israel Sheba MC; Nephrology Ramat-Gan
Israel Sourasky MC; Dept. of Nephrology Tel Aviv
Israel Assaf-Harofeh MC; Nephrology Zrifin
Italy Ospedale S. Marta S. Venera Nuovo; U.O. Nefrologia Dialisi Acireale Sicilia
Italy Ospedale Caduti Bollatesi; U.O. Nefrologia E Dialisi Bollate Lombardia
Italy Ospedale Bernardo Ramazzi; U.O. Di Nefrologia E Dialisi Carpi Emilia-Romagna
Italy Ospedale S. Giacomo; U.O. Di Nefrologia e Dialisi Castelfranco Veneto
Italy Azienda Ospedaliera Cannizzaro Unità Operativa Nefrologia Catania Sicilia
Italy Azienda Ospedaliera Sant'Anna Unità Operativa Complessa di Nefrologia Dialisi Cona (FE) Veneto
Italy P.O. Di Conegliano; U.O. Di Nefrologia E Dialisi Conegliano Veneto
Italy A.O. Universitaria S. Martino Di Genova; Nefrologia Genova Liguria
Italy Ospedale Civile; Servizio Di Nefrologia E Dialisi Imola Emilia-Romagna
Italy ASST DI LECCO; Nefrologia e Dialisi Lecco Lombardia
Italy Presidio Ospedaliero Di Lodi; U.O. Nefrologia E Dialisi Lodi Toscana
Italy A.O.U. Policlinico G.Martino; U.O.C. Nefrologia e Dialisi Messina Sicilia
Italy ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA; Dipartimento di Nefrologia e Dialisi Milano Lombardia
Italy ASST SANTI PAOLO E CARLO; U.O.S. Nefrologia e Dialisi Milano Lombardia
Italy Presidio Ospedaliero Maggiore Policlinico Fondazione IRCCS; Pad Croff Div Nefrologia Dialisi Milano Lombardia
Italy A.O. Universitaria Policlinico Di Modena; Nefrologia E Dialisi Modena Emilia-Romagna
Italy Az. Osp. Di Padova; U.O. Nefrologia 2 E Dialisi Padova Veneto
Italy Ospedale Maggiore; U.O.Complessa di Nefrologia e Dialisi Parma Emilia-Romagna
Italy Fondazione Salvatore Maugeri; Divisione Di Nefrologia E Dialisi Pavia Lombardia
Italy Azienda Ospedaliera San Salvatore; Divisione Nefrologia E Dialisi Pesaro Marche
Italy Ospedale Civile; Divisione de Nefrologia E Dialisi Piacenza Emilia-Romagna
Italy Nuovo Ospedale Di Prato Prato Toscana
Italy Ospedale Provinciale S. Maria delle Croci; Divisione Nefrologia e Dialsi Ravenna Emilia-Romagna
Italy A.O. Santa Maria Nuova Di Reggio Emilia; Unita Operativa Di Nefrologia E Dialisi Reggio Emilia Emilia-Romagna
Italy Universita' Di Tor Vergata; Clinica Nefrologia Dialisi Roma Lazio
Italy Azienda Ospedaliera Santa Maria Misericordia; Divisione Nefrologia Dialisi Rovigo Veneto
Italy ASST LARIANA; Divisione di Nefrologia e Dialisi S Fermo Della Battaglia Lombardia
Italy A.O. Cà Foncello; U.O.Nefrologia, Dialisi e Centro Trapianti Treviso Veneto
Korea, Republic of Samsung Medical Center; Nephrology Department Seoul
Korea, Republic of Seoul National Uni Hospital; Internal Medicine Seoul
Lithuania Hospital of Lithuanian University of Health. Sciences Kaunas Clinics Kaunas
Lithuania Vilnius University Hospital Santariskiu Clinic, Nephrology Center Vilnius
Malaysia Hospital Kuala Lumpur; Department of Medicine Kuala Lumpur
Malaysia University Malaya Medical Centre; Division of Nephrology, Department of Medicine Kuala Lumpur FED. Territory OF Kuala Lumpur
Malaysia Selayang Hospital; Dept of Medicine Selangor
Mexico Investigación Nefrológica S.C. Cuernavaca Morelos
Panama Centro Especializado San Fernando; Nefrología, Diálisis y Trasplante Renal Panama
Philippines Cebu Doctors University Hospital CEBU City
Philippines National Kidney and Transplant Institute Quezon City
Poland Akademia Medyczna; Klinika Nefrologii I Chorob Wewnetrznych Bydgoszcz
Poland Specjalistyczny Szpital Wojewodzki w Ciechanowie; Oddzial Nefrologiczny Ciechanow
Poland Fresenius Nephrocare Polska Sp zo.o.Centrum Dializ Fresenius Osrodek Dializ Nr 45 w Dabrowie Tarn Dabrowa Tarnowska
Poland NZOZ Stacja Dializ Hand-Prod w Gorlicach Gorlice
Poland Fresenius Nephrocare Polska Sp zo.o. Centrum Dializ Fresenius Osrodek Dializ Nr 42 w Jasle Jaslo
Poland NZOZ Stacja Dializ Hand-Prod w Limanowej Limanowa
Poland Fresenius Nephrocare Polska Sp. z o.o., Centrum Dializ Fresenius, Osrodek Dializ nr 53 w Pabianicach Pabianice
Poland Fresenius Nephrocare Polska Sp. z o.o., Centrum Dializ Fresenius, Osrodek Dializ numer 71 w Poznaniu Poznan
Poland Stacja Dializ NZOZ Centrum Medyczne MEDYK Rzeszow
Poland Fresenius Nephrocare Polska Sp.zo.o.Centrum Dializ FreseniusOsrodek Dializ Nr 62 w Sandomierzu Sandomierz
Poland Wojewodzki Szpital Zespolony, Stacja Dializ, Skierniewice Skierniewice
Poland Powiatowy Szpital Specjalistyczny w Stalowej Woli; Oddzial Nefrologii i Dializoterapii Stalowa Wola
Poland Specjalistyczny Szpital im A.Sokolowskiego w Walbrzychu; Oddzial Nefrologiczny Walbrzych
Poland S.P. Szpital Wojewodzki im. Papieza Jana Pawla II Zamosc
Russian Federation SBEI of HPE "Northwestern State Medical University n.a. I.I.Mechnikov" of MoH of RF Saint-Petersburg
Russian Federation SBEI HPE "The First St.Petersburg State Medical University n.a. acad. I.P.Pavlova"of MoH of RF Sankt-peterburg Leningrad
Russian Federation St.Petersburg State Budget Institution of Healthcare "City Hospital Saint Hosiomartyr Elisabeth". St.Petersburg
Russian Federation St.Petersburg State Budget Institution of Healthcare "City Mariinskaya Hospital" St.Petersburg
Serbia Clinical Center of Serbia; Clinic of Urology Belgrade
Serbia Clinical Hospital Center Zvezdara Belgrade
Serbia Zemun Hospital; Nephrology Belgrade
Serbia Clinical Center Nis; Clinic for Nephrology and Hemodialysis NIS
Serbia Clinical Center Voivodina; Clinic for Immunology and Nephrology Novi Sad
Singapore National University Hospital; Dept of Medicine Singapore
Singapore Singapore General Hospital; Renal Medicine Singapore
Singapore Tan Tock Seng Hospital; Department of Renal Medicine Singapore
Spain Complejo Hospitalario Torrecardenas; Servicio de Nefrologia Almería Almeria
Spain Hospital de Cruces; Servicio de Nefrologia Barakaldo Vizcaya
Spain Hospital del Mar; Servicio de Nefrologia Barcelona
Spain Hospital de Basurto; Servicio de Nefrologia Bilbao Vizcaya
Spain Hospital de Galdakano; Servicio de Nefrologia Galdakao Vizcaya
Spain Hospital Universitario San Cecilio Granada
Spain Complejo Hospitalario de Jaen- Hospital Universitario Medico Quirurgico Jaen
Spain Hospital Severo Ochoa; Servicio de Nefrologia Leganes Madrid
Spain Hospital Clinico San Carlos; Servicio de Nefrologia Madrid
Spain Hospital Ramon y Cajal; Servicio de Nefrologia Madrid
Spain Hospital de Navarra; Servicio de Nefrologia Pamplona Navarra
Spain Hospital Infanta Sofia; Servico de Nefrologia San Sebastian de los Reyes Madrid
Spain Hospital Txagorritxu; Servicio de Nefrologia Vitoria Alava
Sweden Danderyds Sjukhus; Dept. of Nephrology Danderyd
Sweden Maelar Hospital; Department of Medicine Eskilstuna
Sweden Uppsala University Hospital; Department of Internal Medicine, Nephrology Section Uppsala
Taiwan Chang Gung Medical Fundation Kaohsiung Branch; Nephrology Kaohsiung
Taiwan National Taiwan Uni Hospital; Nephrology Dept Taipei
Thailand King Chulalongkorn Memorial Hospital; Renal Unit, Department of Medicine Bangkok
Thailand Maharaj Nakorn Chiang Mai Hospital; Dept. of Medicine, Renal Division Chiang Mai
Thailand Buddhachinaraj Hospital Renal Division; Dept of Medicine Phitsanulok
Turkey Cukurova University School of Medicine; Nefrology Department Adana
Turkey Baskent University Hospital; Transplantation Ankara
Turkey Inonu Uni School of Medicine Malatya
United Kingdom Belfast City Hospital; Nephrology Unit Belfast
United Kingdom Ulster Hospital; Nephrology Belfast
United Kingdom St Luke'S Hospital; Renal Unit Bradford
United Kingdom University Hospital of Wales; Institute of Nephrology Cardiff
United Kingdom St Helier Hospital; Renal Unit Carshalton
United Kingdom University Hospital Coventry And Warwickshire Nhs Trust; Department Of Nephrology Coventry
United Kingdom Dorset County Hospital; Renal Unit Dorchester
United Kingdom Royal Devon & Exeter Hospital; Dept of Nephrology Exeter
United Kingdom Hull Royal Infirmary; Renal Medicine Hull
United Kingdom The Ipswich Hospital Nhs Trust; The Renal Unit Ipswich
United Kingdom St James Uni Hospital; Renal Unit Leeds
United Kingdom Leicester General Hospital; Dept of Nephrology Leicester
United Kingdom Royal Free & University College Medical School; Centre for Nephrology London
United Kingdom James Cook Hospital; Nephrology Middlesborough
United Kingdom Freeman Hospital; Nephrology Newcastle Upon Tyne
United Kingdom The Churchill; Oxford Kidney Unit Oxford
United Kingdom Derriford Hospital; Department Of Renal Medicine Plymouth
United Kingdom Royal Preston Hospital; Department of Renal Medicine Preston
United Kingdom Salford Royal Foundation Trust; Department Of Nephrology Salford
United Kingdom Royal Shrewsbury Hospital Shrewsbury
United Kingdom Morriston Hospital; Renal Medicine Swansea
United Kingdom Royal Cornwall Hospital; Renal Unit Truro
United Kingdom Worthing Hospital; Renal Unit West Sussex

Sponsors (1)

Lead Sponsor Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

Argentina,  Australia,  Belgium,  Brazil,  Croatia,  Czechia,  France,  Germany,  Greece,  Israel,  Italy,  Korea, Republic of,  Lithuania,  Malaysia,  Mexico,  Panama,  Philippines,  Poland,  Russian Federation,  Serbia,  Singapore,  Spain,  Sweden,  Taiwan,  Thailand,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events (Myocardial Infarction, Stroke) Defined as Time Between First Dose of Study Medication and Date of Death or Non-Fatal Cardiovascular Events, Whichever Occurred First Baseline up to approximately 8.5 years
Secondary Time to All-Cause Mortality Baseline up to approximately 8.5 years
Secondary Time to Non-Fatal and Fatal Myocardial Infarction Baseline up to approximately 8.5 years
Secondary Time to Non-Fatal and Fatal Stroke Baseline up to approximately 8.5 years
Secondary Time to Non-Fatal Cardiovascular Events (Myocardial Infarction or Stroke, Whichever Occurred First) Baseline up to approximately 8.5 years
Secondary Percentage of Participants With Anti-Erythropoietin Antibody-Mediated Pure Red Cell Aplasia (PRCA) Baseline up to approximately 8.5 years
Secondary Percentage of Participants With Gastrointestinal Bleeding Baseline up to approximately 8.5 years
Secondary Percentage of Participants With Thromboembolic Events Baseline up to approximately 8.5 years